Nimotuzumab on ASCO 2022

Once again, Nimotuzumab’s efficacy and safety in several cancer types were discussed and analyzed thoroughly at this year’s 2022 ASCO Annual Meeting and Discussion. Pancreatic cancer, esophageal squamous cell carcinoma and nasopharyngeal carcinoma became the main topics of discussion. You can find the articles below or visit Innokeys’ website for full information:

1. Nimotuzumab Plus Gemcitabine Improves Survival in KRAS Wild-Type Pancreatic Cancer

   Author: Kristie L. KahlYear: 2022 Published in: ASCO Annual Meeting

2. Nimotuzumab May Improve Overall Survival in Patients With KRAS Wild-Type Advanced Pancreatic Cancer

   Author: Kristie L. KahlYear: 2022 Published in: The ASCO Post

3. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study)

   Author: Xue Meng, Anping Zheng, Jun Wang, et al.Year: 2022 Published in: ASCO Poster Discussion Session

4. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial

   Author: Yan Sun, Chaosu Hu, Qin Lin, et al.Year: 2022 Published in: ASCO Oral Abstract Session